Literature DB >> 31326236

Insights into Computational Drug Repurposing for Neurodegenerative Disease.

Manish D Paranjpe1, Alice Taubes2, Marina Sirota3.   

Abstract

Computational drug repurposing has the ability to remarkably reduce drug development time and cost in an era where these factors are prohibitively high. Several examples of successful repurposed drugs exist in fields such as oncology, diabetes, leprosy, inflammatory bowel disease, among others, however computational drug repurposing in neurodegenerative disease has presented several unique challenges stemming from the lack of validation methods and difficulty in studying heterogenous diseases of aging. Here, we examine existing approaches to computational drug repurposing, including molecular, clinical, and biophysical methods, and propose data sources and methods to advance computational drug repurposing in neurodegenerative disease using Alzheimer's disease as an example.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; EHR; EMR; artificial intelligence; machine learning; transcriptomic analysis

Mesh:

Year:  2019        PMID: 31326236      PMCID: PMC6771436          DOI: 10.1016/j.tips.2019.06.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  121 in total

1.  Missing value estimation methods for DNA microarrays.

Authors:  O Troyanskaya; M Cantor; G Sherlock; P Brown; T Hastie; R Tibshirani; D Botstein; R B Altman
Journal:  Bioinformatics       Date:  2001-06       Impact factor: 6.937

2.  Probabilistic linkage of computerized ambulance and inpatient hospital discharge records: a potential tool for evaluation of emergency medical services.

Authors:  J M Dean; D D Vernon; L Cook; P Nechodom; J Reading; A Suruda
Journal:  Ann Emerg Med       Date:  2001-06       Impact factor: 5.721

3.  Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model.

Authors:  Karen M Mann; Fayanne E Thorngate; Yuko Katoh-Fukui; Hiroki Hamanaka; David L Williams; Shinobu Fujita; Bruce T Lamb
Journal:  Hum Mol Genet       Date:  2004-06-30       Impact factor: 6.150

4.  Aggregation of vascular risk factors and risk of incident Alzheimer disease.

Authors:  J A Luchsinger; C Reitz; L S Honig; M X Tang; Steven Shea; R Mayeux
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

Review 5.  Docking and scoring in virtual screening for drug discovery: methods and applications.

Authors:  Douglas B Kitchen; Hélène Decornez; John R Furr; Jürgen Bajorath
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

6.  Zonisamide has beneficial effects on Parkinson's disease patients.

Authors:  M Murata; E Horiuchi; I Kanazawa
Journal:  Neurosci Res       Date:  2001-12       Impact factor: 3.304

7.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.

Authors:  M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  BMJ       Date:  2001-06-16

8.  Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study.

Authors:  M Shiba; J H Bower; D M Maraganore; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

9.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

10.  Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors.

Authors:  Cheng Song; Yuntian Zhang; Chris G Parsons; Ya Fang Liu
Journal:  J Biol Chem       Date:  2003-06-16       Impact factor: 5.157

View more
  24 in total

Review 1.  Molecular profiling in sarcoidosis.

Authors:  Nicholas K Arger; Brian O'Connor; Laura L Koth
Journal:  Curr Opin Pulm Med       Date:  2020-09       Impact factor: 3.155

2.  An integrated chemo-informatics and in vitro experimental approach repurposes acarbose as a post-ischemic neuro-protectant.

Authors:  Jyotirekha Das; Fayaz Shaik Mahammad; Rajanikant Golgodu Krishnamurthy
Journal:  3 Biotech       Date:  2022-02-15       Impact factor: 2.406

3.  Deficiency of autism-related Scn2a gene in mice disrupts sleep patterns and circadian rhythms.

Authors:  Zhixiong Ma; Muriel Eaton; Yushuang Liu; Jingliang Zhang; Xiaoling Chen; Xinyu Tu; Yiqiang Shi; Zhefu Que; Kyle Wettschurack; Zaiyang Zhang; Riyi Shi; Yueyi Chen; Adam Kimbrough; Nadia A Lanman; Leah Schust; Zhuo Huang; Yang Yang
Journal:  Neurobiol Dis       Date:  2022-03-14       Impact factor: 7.046

4.  Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents.

Authors:  Kushagra Kashyap; Mohammad Imran Siddiqi
Journal:  Mol Divers       Date:  2021-07-19       Impact factor: 3.364

5.  Single Cell and Single Nucleus RNA-Seq Reveal Cellular Heterogeneity and Homeostatic Regulatory Networks in Adult Mouse Stria Vascularis.

Authors:  Soumya Korrapati; Ian Taukulis; Rafal Olszewski; Madeline Pyle; Shoujun Gu; Riya Singh; Carla Griffiths; Daniel Martin; Erich Boger; Robert J Morell; Michael Hoa
Journal:  Front Mol Neurosci       Date:  2019-12-20       Impact factor: 5.639

Review 6.  Diagnostic and Therapeutic Potential of Exosomal MicroRNAs for Neurodegenerative Diseases.

Authors:  Miao He; Hai-Nan Zhang; Zhen-Chu Tang; Shu-Guang Gao
Journal:  Neural Plast       Date:  2021-05-16       Impact factor: 3.599

7.  Reimagining Innovation Amid the COVID-19 Pandemic: Insights From the WISH Innovation Programme.

Authors:  Maha El Akoum; Mahmoud El Achi
Journal:  Front Public Health       Date:  2021-06-07

Review 8.  Digital Pharmaceutical Sciences.

Authors:  Safa A Damiati
Journal:  AAPS PharmSciTech       Date:  2020-07-26       Impact factor: 3.246

9.  Repurposed agents in the Alzheimer's disease drug development pipeline.

Authors:  Justin Bauzon; Garam Lee; Jeffrey Cummings
Journal:  Alzheimers Res Ther       Date:  2020-08-17       Impact factor: 6.982

Review 10.  Translational Genomics in Neurocritical Care: a Review.

Authors:  Pavlos Myserlis; Farid Radmanesh; Christopher D Anderson
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.